| 摘要: |
| ［摘要］ 目的 观察远隔缺血预适应（RIPC）联合依达拉奉治疗脑小血管病（CSVD）的临床效果。方法 招募2018年1月至2023年12月合肥市第二人民医院收治的CSVD患者80例，采用随机数字表法将其分为观察组和对照组，每组40例。对照组接受依达拉奉治疗，观察组接受RIPC联合依达拉奉治疗，两组疗程均为1个月。比较两组治疗前及治疗后3个月的认知功能、脑血流灌注指标、血管内皮功能相关因子和炎症因子水平。比较两组临床疗效及不良反应发生情况。结果 两组治疗后蒙特利尔认知评估量表（MoCA）评分、简易智力状态检查量表（MMSE）评分，以及脑血流速度（CBFV）、脑血流量（CBF）、血管内皮生长因子（VEGF）、一氧化氮（NO）水平均较治疗前升高，且观察组指标水平较对照组更高，差异有统计学意义（P<0.05）。两组治疗后脑血流平均通过时间（MTT）、肿瘤坏死因子-α（TNF-α）、白细胞介素-8（IL-8）水平均较治疗前降低，且观察组指标水平较对照组更低，差异有统计学意义（P<0.05）。观察组临床总有效率显著高于对照组（92.50% vs 72.50%； χ2=5.541，P=0.019）。两组不良反应发生率比较差异无统计学意义（15.00% vs 10.00%； χ2=0.457，P=0.499）。结论 RIPC联合依达拉奉可有效改善CSVD患者认知功能及脑血流灌注状态，减轻炎症反应和血管内皮功能障碍，安全性良好，疗效显著。 |
| 关键词: 脑小血管病 远隔缺血预适应 依达拉奉 疗效 |
| DOI：10.3969/j.issn.1674-3806.2026.08.12 |
| 分类号:R 743 |
| 基金项目:安徽省重点研发项目（编号：2022e07020029） |
|
| Observation on clinical efficacy of remote ischemic preconditioning combined with edaravone in treatment of cerebral small vessel disease |
|
Huang Yuanyuan, Liu Xuechun
|
|
Department of Neurology, the Second People′s Hospital of Hefei, Hefei 232001, China
|
| Abstract: |
| ［Abstract］ Objective To observe the clinical efficacy of remote ischemic preconditioning(RIPC) combined with edaravone in treatment of cerebral small vessel disease(CSVD). Methods A total of 80 patients with CSVD who were admitted to the Second People′s Hospital of Hefei from January 2018 to December 2023 were recruited and divided into observation group and control group by using random number table method, with 40 patients in each group. The control group received edaravone treatment, while the observation group received RIPC combined with edaravone treatment. The treatment course for both groups was 1 month. The cognitive function, cerebral blood flow perfusion indicators, vascular endothelial function-related factors and inflammatory factor levels were compared between the two groups before the treatment and 3 months after the treatment. The clinical efficacy and the occurrence of adverse reactions were compared between the two groups. Results After the treatment, the Montreal Cognitive Assessment(MoCA) scores, the Mini-Mental State Examination(MMSE) scores, as well as cerebral blood flow velocity(CBFV), cerebral blood flow(CBF), vascular endothelial growth factor(VEGF), and nitric oxide(NO) levels in both groups were increased compared with those before the treatment, and the above indicators in the observation group were higher than those in the control group after the treatment, with statistically significant differences(P<0.05). After the treatment, the mean transit time(MTT) of cerebral blood flow, tumor necrosis factor-alpha(TNF-α) and interleukin-8(IL-8) levels in both groups were lower than those before the treatment, and the levels of the above indicators in the observation group were lower than those in the control group after the treatment, with statistically significant differences(P<0.05). The total clinical effective rate of the observation group was significantly higher than that of the control group(92.50% vs 72.50%; χ2=5.541, P=0.019), while there was no statistically significant difference in the incidence of adverse reactions between the two groups(15.00% vs 10.00%; χ2=0.457, P=0.499). Conclusion The combined treatment of RIPC and edaravone can effectively improve the cognitive function and cerebral blood flow perfusion for CSVD patients, alleviate their inflammatory response and vascular endothelial dysfunction, with good safety and significant efficacy. |
| Key words: cerebral small vessel disease(CSVD) remote ischemic preconditioning(RIPC) edaravone efficacy |
